The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design
Open accessAbstract
This review focuses on the important contributions that macromolecular crystallography has made over the past 12 years to elucidating structures and mechanisms of the essential proteases of coronaviruses, the main protease (M pro) and the papain‐like protease (PL pro). The role of X‐ray crystallography in structure‐assisted drug discovery against these targets is discussed. Aspects dealt with in this review include the emergence of the SARS coronavirus in 2002–2003 and of the MERS coronavirus 10 years later and the origins of these viruses. The crystal structure of the free SARS coronavirus M pro and its dependence on pH is discussed, as are efforts to design inhibitors on the basis of these structures. The mechanism of maturation of the enzyme from the viral polyprotein is still a matter of debate. The crystal structure of the SARS coronavirus PL pro and its complex with ubiquitin is also discussed, as is its orthologue from MERS coronavirus. Efforts at predictive structure‐based inhibitor development for bat coronavirus M pro s to increase the preparedness against zoonotic transmission to man are described as well. The paper closes with a brief discussion of structure‐based discovery of antivirals in an academic setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Lau, S. K. P., Poon, R. W., Wong, B. H. L., Wang, M., Huang, Y. P., Xu, H., Guo, R., Li, K. S. M., Gao, K., Chan, K., et al. (2010) · Journal of Virology · doi:10.1128/jvi.01121-10 · Cited by 111
RetractedIsolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,735
Identification of a novel coronavirus in patients with severe acute respiratory syndrome
Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030747 · Cited by 4,574
A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
Ksiazek, T. G., Erdman, D., Goldsmith, C. S., Zaki, S. R., Peret, T., Emery, S., Tong, S., Urbani, C., Comer, J. A., Lim, W., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030781 · Cited by 4,344
Coronavirus as a possible cause of severe acute respiratory syndrome
Peiris, J., Lai, S., Poon, L., Guan, Y., Yam, L., Lim, W., Nicholls, J., Yee, W., Yan, W., Cheung, M., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13077-2 · Cited by 2,915
Bats Are Natural Reservoirs of SARS-Like Coronaviruses
Li, W., Shi, Z., Yu, M., Ren, W., Smith, C., Epstein, J. H., Wang, H., Crameri, G., Hu, Z., Zhang, H., et al. (2005) · Science · doi:10.1126/science.1118391 · Cited by 2,560
Guan, Y., Zheng, B. J., He, Y. Q., Liu, X. L., Zhuang, Z. X., Cheung, C. L., Luo, S. W., Li, P. H., Zhang, L. J., Guan, Y. J., et al. (2003) · Science · doi:10.1126/science.1087139 · Cited by 2,406
Identification of a new human coronavirus
van der Hoek, L., Pyrc, K., Jebbink, M. F., Vermeulen-Oost, W., Berkhout, R. J. M., Wolthers, K. C., Wertheim-van Dillen, P. M. E., Kaandorp, J., Spaargaren, J., & Berkhout, B. (2004) · Nature Medicine · doi:10.1038/nm1024 · Cited by 1,886
Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor
Ge, X.-Y., Li, J.-L., Yang, X.-L., Chmura, A. A., Zhu, G., Epstein, J. H., Mazet, J. K., Hu, B., Zhang, W., Peng, C., et al. (2013) · Nature · doi:10.1038/nature12711 · Cited by 1,778
Coronavirus Main Proteinase (3CL pro ) Structure: Basis for Design of Anti-SARS Drugs
Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. R., & Hilgenfeld, R. (2003) · Science · doi:10.1126/science.1085658 · Cited by 1,728
Self-citation
Cited by
SARS and MERS: recent insights into emerging coronaviruses
de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510
Zhang, L., Lin, D., Sun, X., Curth, U., Drosten, C., Sauerhering, L., Becker, S., Rox, K., & Hilgenfeld, R. (2020) · Science · doi:10.1126/science.abb3405 · Cited by 2,895
Self-citationOral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Hammond, J., Leister-Tebbe, H., Gardner, A., Abreu, P., Bao, W., Wisemandle, W., Baniecki, M., Hendrick, V. M., Damle, B., Simón-Campos, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2118542 · Cited by 2,323
Coronaviruses — drug discovery and therapeutic options
Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K.-Y. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.37 · Cited by 1,707
The SARS-CoV-2 main protease as drug target
Ullrich, S., & Nitsche, C. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127377 · Cited by 772
Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein
Lei, J., Kusov, Y., & Hilgenfeld, R. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2017.11.001 · Cited by 727
Self-citationThe Nonstructural Proteins Directing Coronavirus RNA Synthesis and Processing
Snijder, E. J., Decroly, E., & Ziebuhr, J. (2016) · Advances in Virus Research · doi:10.1016/bs.aivir.2016.08.008 · Cited by 558
Yoshimoto, F. K. (2020) · The Protein Journal · doi:10.1007/s10930-020-09901-4 · Cited by 543
Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease
Douangamath, A., Fearon, D., Gehrtz, P., Krojer, T., Lukacik, P., Owen, C. D., Resnick, E., Strain-Damerell, C., Aimon, A., Ábrányi-Balogh, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18709-w · Cited by 526
Wang, J. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00179 · Cited by 498
Kneller, D. W., Phillips, G., O’Neill, H. M., Jedrzejczak, R., Stols, L., Langan, P., Joachimiak, A., Coates, L., & Kovalevsky, A. (2020) · Nature Communications · doi:10.1038/s41467-020-16954-7 · Cited by 474
Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors
Osipiuk, J., Azizi, S.-A., Dvorkin, S., Endres, M., Jedrzejczak, R., Jones, K. A., Kang, S., Kathayat, R. S., Kim, Y., Lisnyak, V. G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21060-3 · Cited by 462
Rut, W., Lv, Z., Zmudzinski, M., Patchett, S., Nayak, D., Snipas, S. J., El Oualid, F., Huang, T. T., Bekes, M., Drag, M., et al. (2020) · Science Advances · doi:10.1126/sciadv.abd4596 · Cited by 459
COVID-19: Drug Targets and Potential Treatments
Gil, C., Ginex, T., Maestro, I., Nozal, V., Barrado-Gil, L., Cuesta-Geijo, M. Á., Urquiza, J., Ramírez, D., Alonso, C., Campillo, N. E., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00606 · Cited by 445
SARS-CoV-2 M pro inhibitors with antiviral activity in a transgenic mouse model
Qiao, J., Li, Y.-S., Zeng, R., Liu, F.-L., Luo, R.-H., Huang, C., Wang, Y.-F., Zhang, J., Quan, B., Shen, C., et al. (2021) · Science · doi:10.1126/science.abf1611 · Cited by 465
Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
Kandeel, M., & Al-Nazawi, M. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117627 · Cited by 412
Recent discovery and development of inhibitors targeting coronaviruses
Pillaiyar, T., Meenakshisundaram, S., & Manickam, M. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.01.015 · Cited by 361
Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors
Bhardwaj, V. K., Singh, R., Sharma, J., Rajendran, V., Purohit, R., & Kumar, S. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1766572 · Cited by 347
Goyal, B., & Goyal, D. (2020) · ACS Combinatorial Science · doi:10.1021/acscombsci.0c00058 · Cited by 344
Crystal structure of SARS-CoV-2 papain-like protease
Gao, X., Qin, B., Chen, P., Zhu, K., Hou, P., Wojdyla, J. A., Wang, M., & Cui, S. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.08.014 · Cited by 336
Kirtipal, N., Bharadwaj, S., & Kang, S. G. (2020) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2020.104502 · Cited by 306
SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging
Rut, W., Groborz, K., Zhang, L., Sun, X., Zmudzinski, M., Pawlik, B., Wang, X., Jochmans, D., Neyts, J., Młynarski, W., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-020-00689-z · Cited by 301
Self-citationOudshoorn, D., Rijs, K., Limpens, R. W. A. L., Groen, K., Koster, A. J., Snijder, E. J., Kikkert, M., & Bárcena, M. (2017) · mBio · doi:10.1128/mbio.01658-17 · Cited by 245
Mhatre, S., Srivastava, T., Naik, S., & Patravale, V. (2021) · Phytomedicine · doi:10.1016/j.phymed.2020.153286 · Cited by 263
Could Vitamins Help in the Fight Against COVID-19?
Jovic, T. H., Ali, S. R., Ibrahim, N., Jessop, Z. M., Tarassoli, S. P., Dobbs, T. D., Holford, P., Thornton, C. A., & Whitaker, I. S. (2020) · Nutrients · doi:10.3390/nu12092550 · Cited by 234
Metadata
- Authors
- Hilgenfeld, R.
- Venue
- The FEBS Journal
- Publisher
- Wiley
- Published
- 2014-08-11
- Volume
- 281
- Issue
- 18
- Pages
- 4085-4096
- ISSN
- 1742-464X (ISSN-L)
- 1742-4658
- OpenAlex
- W2163761019
- Cited by
- 660
- References
- 79
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.